Navigation Links
Jennerex Announces First Patient Treated in Phase 2a Clinical Trial of JX-594 as a Neoadjuvant Therapy in Colorectal Cancer Patients Undergoing Surgery
Date:12/21/2011

SAN FRANCISCO, Dec. 21, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 2a clinical trial of JX-594 as a neoadjuvant therapy in patients who are undergoing surgery to treat colorectal cancer that has spread to the liver.

The study is being led by Rebecca Auer, M.D., surgical oncologist at The Ottawa Hospital, associate scientist at the Ottawa Hospital Research Institute and assistant professor of surgery at the University of Ottawa in Ottawa, Canada.  The clinical trial is being supported by funding from the Ontario Institute for Cancer Research­.

"This trial will allow us to evaluate the use of JX-594 in patients with surgically resectable disease, potentially expanding the role of this therapy in the treatment continuum," said David H. Kirn, M.D., president and chief medical officer of Jennerex.  "We continue to believe that JX-594 could play an integral role in the treatment of cancers and look forward to the results of this trial along with data from the larger Phase 2b study, called TRAVERSE, that is under way in patients with advanced hepatocellular carcinoma."

"In addition, this study will allow us to expand our analysis of the multi-mechanistic therapeutic activity of JX-594 through the examination of tumor specimens collected during surgery following JX-594 administration," said John C. Bell, Ph.D., senior scientist, cancer therapeutics, Ottawa Hospital Research Institute, and professor of medicine, University of Ottawa.  Dr. Bell is also the program leader of the Ontario Institute for Cancer Research's Immuno- and Bio-therapies Program.

This Phase 2a clinical trial will enroll approximately 20 patients with colorectal cancer metastases to the liver. Patients will receive a single
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
2. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
3. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
6. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
7. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
8. Jennerex Announces Presentations at Upcoming Conferences
9. Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
10. Jennerex Appoints Lara Longpre to Chief Operating Officer
11. Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 4, 2015 Sanomedics , ... a medical technology company that focuses on providing ... that the Company,s subsidiary, Thermomedics, Inc. , has ... and Government Sales. LeBel will be reporting to ... Sales, and will be responsible for supporting assigned ...
(Date:3/4/2015)... DIEGO , March 4, 2015  Imprimis Pharmaceuticals, ... focused on the development and commercialization of proprietary compounded ... fourth quarter and fiscal year 2014 financial results on ... conference call at 4:30 p.m. EDT (1:30 p.m. PDT) ... and report on recent business activities.  The conference call ...
(Date:3/4/2015)... DUBLIN , March 4, 2015   Mallinckrodt ... specialty biopharmaceutical company, will present at the Barclays Global ... Miami, Florida , on Wednesday, March 11, ... will represent the company in a session scheduled to ... cannot attend the meeting in person can find webcast ...
Breaking Medicine Technology:Sanomedics Hires Scott W. LeBel as Director of Specialty and Government Sales 2Sanomedics Hires Scott W. LeBel as Director of Specialty and Government Sales 3Imprimis Pharmaceuticals to Host its Fourth Quarter and Fiscal Year 2014 Financial Report Conference Call and Webcast on March 12, 2015 at 4:30 p.m. EDT 2Imprimis Pharmaceuticals to Host its Fourth Quarter and Fiscal Year 2014 Financial Report Conference Call and Webcast on March 12, 2015 at 4:30 p.m. EDT 3Mallinckrodt to Present at Barclays Conference March 11 2
... Wound Management Technologies, Inc., (OTCQB: WNDM | WNDM.PK) ... that Pharma Tech International (PTI), a joint venture of ... $500,000 minimum sales agreement with Cure Hands, a company ... In the agreement, Pharma Tech International, the exclusive distributor ...
... A poster entitled, "Time to Progression in ... versus Degarelix Following Leuprolide Treatment," is being presented ... David Crawford, MD, head of the Section of Urologic ... in Denver, and lead study investigator. The full manuscript ...
Cached Medicine Technology:International Sales Agreement Signed by WNDM Subsidiary; $500K First-Year Sales Commitment 2International Sales Agreement Signed by WNDM Subsidiary; $500K First-Year Sales Commitment 3International Sales Agreement Signed by WNDM Subsidiary; $500K First-Year Sales Commitment 4Exploratory Efficacy Analysis Conducted for Long-Term Extension Study in Patients With Prostate Cancer Treated With FIRMAGON® or Crossed Over to FIRMAGON From Leuprolide 2Exploratory Efficacy Analysis Conducted for Long-Term Extension Study in Patients With Prostate Cancer Treated With FIRMAGON® or Crossed Over to FIRMAGON From Leuprolide 3Exploratory Efficacy Analysis Conducted for Long-Term Extension Study in Patients With Prostate Cancer Treated With FIRMAGON® or Crossed Over to FIRMAGON From Leuprolide 4Exploratory Efficacy Analysis Conducted for Long-Term Extension Study in Patients With Prostate Cancer Treated With FIRMAGON® or Crossed Over to FIRMAGON From Leuprolide 5
(Date:3/4/2015)... (PRWEB) March 04, 2015 Starting February ... LASIK and PRK procedures at their new location in ... Dr. Joseph King and Dr. Gabriel Chu also provide ... in Surrey is named Fraser Valley Cataract and Laser ... accredited by the College of Physicians and Surgeons of ...
(Date:3/4/2015)... Alliance Healthcare Foundation (AHF), a non-profit organization working ... in San Diego and Imperial Counties, announced today that ... Grants program with awards totaling $1 million. , ... Support Grants program. Grant recipients were chosen through a ... committee, as well as the community as a whole. ...
(Date:3/4/2015)... " Optrix by Body Glove ” ... Tech Report, which takes a look at the latest ... Scott Steinberg, a special reporter for NewsWatch and a ... viewers how they have an ultra-rugged, waterproof case with ... a major player at the Consumer Electronics Show in ...
(Date:3/4/2015)... As seen on Advanced Fertility Center ... a painful condition in which the lining of the ... leading to very unpleasant symptoms and complications that greatly ... terrible effect on women’s quality of life due to ... cause of infertility in women and carries a huge ...
(Date:3/4/2015)... 04, 2015 The New Mel Brooks ... music, will be performed by the award-winning Drama Department ... this March 6-22, 2015, on Fridays, Saturdays and Sundays. ... High School (27118 Silver Spur Road, Rolling Hills ... the program or may be purchased on-line at ...
Breaking Medicine News(10 mins):Health News:King LASIK relocates to Surrey, British Columbia 2Health News:Alliance Healthcare Foundation Awards $1 million through Mission Support Grants Program 2Health News:Alliance Healthcare Foundation Awards $1 million through Mission Support Grants Program 3Health News:A Waterproof Phone Case with an Interchangeable Lens System was Featured on NewsWatch Television on January 30, 2015 2Health News:Advanced Fertility Center of Texas Brings Awareness to the Month of March-Endometriosis Awareness Month 2Health News:Advanced Fertility Center of Texas Brings Awareness to the Month of March-Endometriosis Awareness Month 3Health News:The New Mel Brooks Musical Young Frankenstein Performance March 6-March 22, 2015, by the Award Winning Drama Department at Peninsula High School, Rolling Hills 2
... still looking for a date for Valentine,s Day? Here,s some dating ... something to "playing hard to get." A study published in ... finds that a woman is more attracted to a man when ... On the one hand, a lot of psychological research has found ...
... million, five-year grant from the National Cancer Institute will ... called Latinos Contra El Cancer, to reduce cancer-related health ... a joint project of The University of Texas Health ... and The University of Texas MD Anderson Cancer Center. ...
... 7, 2011 Geneva, Switzerland. Following the publication of ... fraud discovered in grants financed by the Global Fund ... Society (IAS) urges all donors and governments to continue ... and innovative financing instrument which attracts, manages and disburses ...
... A digital signal processing technique long used by statisticians ... roots of memory and learning, Alzheimer,s and Parkinson,s diseases ... University of Texas Health Science Center at Houston (UTHealth) ... that single molecule fluorescence resonance energy transfer (FRET) ...
... works, an anthropologist tackles a perplexing question relating to the ... and even celebrate the public display of human corpses? ... Human Bodies " is the most widely attended exhibit in ... anthropology at the University of Illinois and author of a ...
... , MONDAY, Feb. 7 (HealthDay News) -- Living ... health risks such as smoking or obesity, researchers have ... families, Cornell University researchers asked 17-year-olds and their mothers ... measure of how connected their community is and the ...
Cached Medicine News:Health News:'He loves me, he loves me not...': Women are more attracted to men whose feelings are unclear 2Health News:Project connects researchers, Latino communities to prevent cancer 2Health News:Project connects researchers, Latino communities to prevent cancer 3Health News:Media reports ignore that Global Fund resources deliver tremendous results in the fight against AIDS 2Health News:Researchers get a grip on nervous system's receptors 2Health News:Researchers get a grip on nervous system's receptors 3Health News:Anthropologist: 'Body Worlds' visitors confront bodies but not death 2Health News:Anthropologist: 'Body Worlds' visitors confront bodies but not death 3Health News:Community Has a Role in Health of Low-Income Kids 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: